PCSA vs PCVX

Processa Pharmaceuticals, Inc. vs Vaxcyte, Inc. — Valuation Comparison 2026

PCSA

Biotechnology
Processa Pharmaceuticals, Inc.
Quality
3.7
out of 10
Value Trap
24
SAFE
Price
$2.64
Last close
Models
7/13
Active
VS

PCVX

Biotechnology
Vaxcyte, Inc.
Quality
5.1
out of 10
Value Trap
12
SAFE
Price
$51.06
Last close
Models
10/13
Active

Model-by-Model Comparison

ModelType PCSA Fair ValuePCSA Upside PCVX Fair ValuePCVX Upside
Bayesian DCF Intrinsic $1.04 -60.5% $16.06 -68.6%
Earnings Power Value Intrinsic $27.17 -54.3%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.20 -93.4% $11.30 -77.9%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PCSA vs PCVX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PCSA vs PCVX — Which Stock Is More Undervalued?

PCVX scores higher with a 5.1/10 quality rating vs PCSA's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Processa Pharmaceuticals, Inc. (PCSA) and Vaxcyte, Inc. (PCVX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PCSA currently trades at $2.64 with a QOC of 3.7/10, while PCVX trades at $51.06 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).